The DOI matches its Crossref record; 58 of the 60 references it cites were found in a registry or an index.
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
Open accessAbstract
Previous studies have shown that the translation level of in vitro transcribed messenger RNA (mRNA) is enhanced when its uridines are replaced with pseudouridines; however, the reason for this enhancement has not been identified. Here, we demonstrate that in vitro transcripts containing uridine activate RNA-dependent protein kinase (PKR), which then phosphorylates translation initiation factor 2-alpha (eIF-2α), and inhibits translation. In contrast, in vitro transcribed mRNAs containing pseudouridine activate PKR to a lesser degree, and translation of pseudouridine-containing mRNAs is not repressed. RNA pull-down assays demonstrate that mRNA containing uridine is bound by PKR more efficiently than mRNA with pseudouridine. Finally, the role of PKR is validated by showing that pseudouridine- and uridine-containing RNAs were translated equally in PKR knockout cells. These results indicate that the enhanced translation of mRNAs containing pseudouridine, compared to those containing uridine, is mediated by decreased activation of PKR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Substitution of chemically modified nucleotides in messenger ribonucleic acid (mRNA) enhances stability and transfection capability, and decreases immunogenicity1–3”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Native RNA activates pattern recognition receptors such as toll-like receptors and triggers type I interferon (IFN) production, resulting in translational shutoff and systemic inflammation3.”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This can be circumvented by the incorporation of naturally occurring nucleosides and by applying stringent purification to remove double-stranded RNA contaminants (19–21).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Transferring this concept to in vitro transcribed mRNA, for instance, pseudouridine-containing mRNAs reduced activation of known RNA sensors substantially.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two uridine analogs pseudouridine (Ψ) or 1-methyl-pseudouridine (m1Ψ) are widely used for mRNA therapeutics because they can increase mRNA stability and help modulate the host immune response31,32.”
From Human 5′ UTR design and variant effect prediction from a massively parallel translation assay (2019) · cites this paper as [32]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Although pseudouridine is primarily found in tRNA, rRNA, and small nuclear RNAs, pseudouridine-containing mRNAs were still translated and produced even more protein compared to unmodified mRNA.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, nucleoside modifications are well known to limit or even inhibit RNA sensor engagement.20,21,22”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [22]
In the citing paper
“Nucleoside-modified mRNA can reduce the activation of TLRs, retinoic acid-inducible gene I (RIG-I), protein kinase R (PKR), and 2′-5′-oligoadenylate synthetase (OAS). Additionally, nucleoside modification increases translation activity and resistance against RNase L-mediated degradation.54,81,173–176”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [174]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citation5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationActivation of the interferon system by short-interfering RNAs
Sledz, C. A., Holko, M., de Veer, M. J., Silverman, R. H., & Williams, B. R. G. (2003) · Nature Cell Biology · doi:10.1038/ncb1038 · Cited by 1,401
AAV vector integration sites in mouse hepatocellular carcinoma
Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., & Sands, M. S. (2007) · Science · doi:10.1126/science.1142658 · Cited by 662
Pseudouridine in RNA: What, Where, How, and Why
Charette, M., & Gray, M. W. (2000) · IUBMB Life · doi:10.1080/152165400410182 · Cited by 600
Ryter, J. M., & Schultz, S. C. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7505 · Cited by 479
The RNA Modification Database: 1999 update
Rozenski, J., Crain, P. F., & McCloskey, J. A. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.196 · Cited by 390
2′-O-methyl-modified RNAs Act as TLR7 Antagonists
Robbins, M., Judge, A. D., Liang, L. Y., McClintock, K., Yaworski, E., & MacLachlan, I. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300240 · Cited by 339
Genotoxicity of Retroviral Integration In Hematopoietic Cells
Nienhuis, A. W., Dunbar, C. E., & Sorrentino, B. P. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.001 · Cited by 301
Flagged first, then by citations
2 of the 60 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 684
Optimal Chimeric Antigen Receptor (CAR)-mRNA for Transient CAR T Cell Generation
Kitte, R., Serfling, R., Blache, U., Seitz, C., Schrader, S., Koehl, U., Fricke, S., Bär, C., & Tretbar, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26030965 · Cited by 18
Physical and chemical advances of synthetic delivery vehicles to enhance mRNA vaccine efficacy
Kim, H. J., Seo, S. K., & Park, H. Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.029 · Cited by 18
Gu, J., Xu, Z., Liu, Q., Tang, S., Zhang, W., Xie, S., Chen, X., Chen, J., Yong, K., Yang, C., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302409 · Cited by 20
RNA modifications: emerging players in the regulation of reproduction and development
Wen, J., Zhu, Q., Liu, Y., & Gou, L. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024201 · Cited by 20
DNA-terminus-dependent transcription by T7 RNA polymerase and its C-helix mutants
Yu, B., Chen, Y., Yan, Y., Lu, X., & Zhu, B. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae593 · Cited by 17
Alameh, M., & Weissman, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821595-1.00014-2 · Cited by 17
Self-citationMokuda, S., Watanabe, H., Kohno, H., Ishitoku, M., Araki, K., Hirata, S., & Sugiyama, E. (2022) · Cytotechnology · doi:10.1007/s10616-022-00540-4 · Cited by 16
Lin, P. J. C., & Tam, Y. K. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.108 · Cited by 18
Denzinger, M., Link, A., Kurz, J., Krauß, S., Thoma, R., Schlensak, C., Wendel, H. P., & Krajewski, S. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0737 · Cited by 17
Grudzinska‐Goebel, J., Braun, M., Chen, L., Gupta, S., Lohmann, S., Morais, P., Niu, T., Tarcsa, E., Tourdot, S., Youssef, A. S., et al. (2025) · Nucleic Acid Therapeutics · doi:10.1177/21593337251387423 · Cited by 17
Drzeniek, N. M., Kahwaji, N., Schlickeiser, S., Reinke, P., Geißler, S., Volk, H., & Gossen, M. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121971 · Cited by 16
Solodushko, V., & Fouty, B. (2023) · Gene Therapy · doi:10.1038/s41434-023-00391-4 · Cited by 18
The regulation of antiviral innate immunity through non-m6A RNA modifications
Shen, S., & Zhang, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1286820 · Cited by 17
mRNA biotherapeutics landscape for rare genetic disorders
Iyer, V. R., Praveen Reddy., P., Kaduskar, B., Moharir, S. C., & Mishra, R. K. (2024) · Journal of Biosciences · doi:10.1007/s12038-023-00415-6 · Cited by 17
Messenger RNA as a Novel Therapeutic Approach
Stanton, M. G., & Murphy-Benenato, K. E. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_30 · Cited by 16
LINE-1 RNA triggers matrix formation in bone cells via a PKR-mediated inflammatory response
Mangiavacchi, A., Morelli, G., Reppe, S., Saera-Vila, A., Liu, P., Eggerschwiler, B., Zhang, H., Bensaddek, D., Casanova, E. A., Medina‐Gómez, C., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00143-z · Cited by 16
Artificial intelligence for nanomedicine
Song, X., Gao, X., Wang, H., Yu, F., Qin, M., Li, Y., Liu, Y., Feng, W., Zhou, C., Chukavin, N. N., et al. (2025) · Science China Chemistry · doi:10.1007/s11426-025-2942-5 · Cited by 16
Moore, S. T., Lian, X., Vaidya, A., Chatterjee, S., Santelli, J., Sun, Y., Farbiak, L., Zhu, H., & Siegwart, D. J. (2026) · Nature Communications · doi:10.1038/s41467-025-68103-7 · Cited by 16
New vector and vaccine platforms: mRNA, DNA, viral vectors
Hanke, T. (2022) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000763 · Cited by 15
Translation of in vitro-transcribed RNA therapeutics
von der Haar, T., Mulroney, T. E., Hedayioglu, F. D. L., Kurusamy, S., Rust, M., Lilley, K. S., Thaventhiran, J. E. D., Willis, A. E., & Smales, C. M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1128067 · Cited by 14
Virus-Derived Small RNAs and microRNAs in Health and Disease
Gouzouasis, V., Tastsoglou, S., Giannakakis, A., & Hatzigeorgiou, A. G. (2023) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-122220-111429 · Cited by 14
Benčić, P., Keppler, M., Kuge, M., Qiu, D., Schütte, L. M., Häner, M., Strack, K., Jessen, H. J., Andexer, J. N., & Loenarz, C. (2023) · FEBS Journal · doi:10.1111/febs.16889 · Cited by 15
Yuan, X., Wu, Z., Guo, J., Luo, D., Li, T., Cao, Q., Ren, X., Fang, H., Xu, D., & Cao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202303321 · Cited by 13
RNA pseudouridine modification in plants
Niu, Y., & Liu, L. (2023) · Journal of Experimental Botany · doi:10.1093/jxb/erad323 · Cited by 16
Metabolic Engineering of Escherichia coli for Efficient Production of Pseudouridine
Min, Z., Tang, R., Wei, L., Wang, J., & Qi, H. (2023) · ACS Omega · doi:10.1021/acsomega.3c05219 · Cited by 15
RNA vaccines: A transformational advance
Brown, B. D., Fauci, A. S., Belkaid, Y., & Mérad, M. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.009 · Cited by 15
Phosphorothioate RNA Analysis by NETD Tandem Mass Spectrometry
Peters-Clarke, T. M., Quan, Q., Anderson, B. J., McGee, W. M., Lohr, E., Hebert, A. S., Westphall, M. S., & Coon, J. J. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100742 · Cited by 15
Self-citationRNA Engineering for Public Health: Innovations in RNA-Based Diagnostics and Therapeutics
Thavarajah, W., Hertz, L. M., Bushhouse, D. Z., Archuleta, C. M., & Lucks, J. B. (2021) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-101420-014055 · Cited by 15
Innate sensing of mRNA vaccines
Wuebben, C., Bartok, E., & Hartmann, G. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102249 · Cited by 16
Cell Engineering with Synthetic Messenger RNA
Rabinovich, P. M., & Weissman, S. M. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_1 · Cited by 15
Ma, Q., Li, R., Guo, J., Li, M., Ma, L., Dai, J., Shi, Y., Dai, J., Huang, Y., Dai, C., et al. (2022) · Vaccines · doi:10.3390/vaccines10101698 · Cited by 13
Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16
Zhang, Y., Yan, H., Wei, Z. C., Hong, H., Huang, D., Liu, G., Qin, Q., Rong, R., Gao, P., Meng, J., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132433 · Cited by 14
Non-viral vectors for chimeric antigen receptor immunotherapy
Tretbar, S., Rurik, J. G., Rustad, E. H., Sürün, D., Koehl, U., Olweus, J., Buchholz, F., Ivics, Z., Fricke, S., & Blache, U. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00348-w · Cited by 15
Rationalizing the effects of RNA modifications on protein interactions
Vandelli, A., Broglia, L., Armaos, A., Ponti, R. D., & Tartaglia, G. G. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102391 · Cited by 14
Innate Sensing of Viral Nucleic Acids and Their Use in Antiviral Vaccine Development
Enya, T., & Ross, S. R. (2025) · Vaccines · doi:10.3390/vaccines13020193 · Cited by 15
Anti-Idiotypic mRNA Vaccine to Treat Autoimmune Disorders
Niazi, S. K. (2023) · Vaccines · doi:10.3390/vaccines12010009 · Cited by 16
Michel, T., Kankura, A., Medina, M. L. S., Kurz, J., Behring, A., Avci‐Adali, M., Nolte, A., Schlensak, C., Wendel, H. P., & Krajewski, S. (2015) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0537 · Cited by 14
Corritore, E., Lee, Y.-S., Pasquale, V., Liberati, D., Hsu, M., Lombard, C. A., Smissen, P. V. D., Vetere, A., Bonner‐Weir, S., Piemonti, L., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0318 · Cited by 14
Advances and Strategies in Enhancing mRNA Cancer Vaccines
Zhang, M., Chen, S., Hu, H.-J., Ong, Y., & Ni, Q. (2025) · Advanced Materials · doi:10.1002/adma.202509880 · Cited by 17
Protective RNA nanovaccines against Mycobacterium avium subspecies hominissuis
Touray, B. J. B., Hanafy, M., Phanse, Y., Hildebrand, R., & Talaat, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188754 · Cited by 14
Schievelbein, M., Resende, C., Glennon, M. M., Kerosky, M., & Brown, J. A. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105548 · Cited by 12
Wang, S., Guo, B., Wang, H., & Yang, F. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105547 · Cited by 14
Norimatsu, J., Mizuno, H. L., Watanabe, T., Obara, T., Nakakido, M., Tsumoto, K., Cabral, H., Kuroda, D., & Anraku, Y. (2024) · Materials Horizons · doi:10.1039/d4mh00325j · Cited by 14
Molecular Dynamics Simulation of Lipid Nanoparticles Encapsulating mRNA
Zhang, Z., Cheng, D., Luo, W., Hu, D., Yang, T., Hu, K., Liang, L., Liu, W., & Hu, J. (2024) · Molecules · doi:10.3390/molecules29184409 · Cited by 13
Regulating Immune Responses Induced by PEGylated Messenger RNA–Lipid Nanoparticle Vaccine
Jo, H., Jeoung, J., Kim, W., & Jeoung, D. (2024) · Vaccines · doi:10.3390/vaccines13010014 · Cited by 17
Zhang, Y., Xi, X., Yu, H., Yang, L., Lin, J., Yang, W., Liu, J., Fan, X., & Xu, Y. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.017 · Cited by 13
Prokhorova, D. V., Vokhtantsev, I. P., Tolstova, P. O., Zhuravlev, E. S., Kulishova, L. M., Zharkov, D. O., & Stepanov, G. A. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0069 · Cited by 13
Delehedde, C., Ciganek, I., Rameix, N., Laroui, N., Gonçalves, C., Even, L., Midoux, P., & Pichon, C. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123531 · Cited by 14
Maurer, J., Vanluchene, H., Tsalmpouris, A., Morreel, K., Camperi, J., Sandra, K., & Guillarme, D. (2025) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2025.118309 · Cited by 13
In Silico Methods, Simulations, and Design of Drug‐Delivery Nanocarriers
Song, X., Liu, P., Zhang, X., Zhou, Y., Qian, H., Yang, K., Zhang, X., Gao, X., Zheng, J., Shi, X., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202523068 · Cited by 13
Palm, S. M., Horton, C. A., Zhang, X., & Collins, K. (2024) · RNA · doi:10.1261/rna.080031.124 · Cited by 13
The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize
Janowski, M., & Andrzejewska, A. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.003 · Cited by 12
Modified mRNA as a Treatment for Myocardial Infarction
Wang, Y., Wu, M., & Guo, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054737 · Cited by 12
Processing of Double-Stranded RNA in Mammalian Cells: A Direct Antiviral Role?
Gantier, M. P. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0003 · Cited by 12
Synthetic mRNA: Production, Introduction into Cells, and Physiological Consequences
Rhoads, R. E. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3625-0_1 · Cited by 11
Luo, Z., Bian, Y., Zheng, G., Wang, H., Yan, B., Su, W., Dong, W., Hu, Z., Ding, J. H., Wang, A., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.623959 · Cited by 12
Bispecific antibody targeting of lipid nanoparticlesPreprint
Amabile, A., Phelan, M., Yu, Z., Silva, P., Marks, A. R., Morlà‐Folch, J., Sohn, M., Mollaoglu, G., Falcomatà, C., Teunissen, A. J. P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.20.629467 · Cited by 14
Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors
Wang, S., Xu, X., Viitala, T., Shu, Y., & Zhang, H. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102737 · Cited by 14
Epitranscriptomic control of cancer immunity and therapy resistance
Zhao, X., & Guan, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1706557 · Cited by 11
N1-Methylpseudouridine directly modulates translation dynamics
Rozman, B., Broennimann, K., Rajan, K. S., Nachshon, A., Saha, C., Arazi, T., Mohan, V., Geiger, T., Wollner, C. J., Richner, J. M., et al. (2026) · Nature · doi:10.1038/s41586-025-09945-5 · Cited by 15
Park, J. K., Lee, E. B., & Winthrop, K. L. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2024-225492 · Cited by 12
Comprehensive chromatographic assessment of forced degraded in vitro transcribed mRNA
Dayeh, D. M., Cika, J., Moon, Y., Henderson, S., Grandi, D. D., Fu, Y., Muthusamy, K., Palackal, N. T., Ihnat, P. M., & Pyles, E. A. (2024) · Journal of Chromatography A · doi:10.1016/j.chroma.2024.464885 · Cited by 11
Potential Application of Modified mRNA in Cardiac Regeneration
Wang, A. Y. L., Chang, Y., Chen, K., & Loh, C. Y. Y. (2024) · Cell Transplantation · doi:10.1177/09636897241248956 · Cited by 12
Grigoriev, V., Korzun, T., Moses, A. S., Jozić, A., Zhu, X., Kim, J., Newton, S., Eygeris, Y., Diba, P., Sattler, A. L., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c06930 · Cited by 11
Research progress of mosquito-borne virus mRNA vaccines
Sun, N., Su, Z., & Zheng, X. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101398 · Cited by 11
Versteeg, L., Adhikari, R., Robinson, G., Lee, J., Wei, J., Islam, N., Keegan, B. P., Russell, W. K., Poveda, C., Villar, M. J., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012764 · Cited by 11
Stiving, A. Q., Roose, B. W., Tubbs, C. M., Haverick, M. A., Gruber, A., Rustandi, R. R., Kuiper, J. L., Schombs, M. W., Schuessler, H. A., & Li, X. (2025) · npj Vaccines · doi:10.1038/s41541-025-01082-4 · Cited by 15
Amini, A., Garner, L. C., Shaw, R. H., Kelly, N. E. W., Adele, S., Skelly, D., Dejnirattisai, W., Greenland, M., Liu, X., Heslington, A., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adu3337 · Cited by 12
Liu, Y., Liu, X., Huang, J., Shi, Y., Luo, Z., Zhang, J., Guo, X., Jiang, M., Li, X., Yin, H., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202202460 · Cited by 11
Aging-induced pseudouridine synthase 10 impairs hematopoietic stem cells
Wang, Y., Zhang, Z., He, H., Song, J., Cui, Y., Chen, Y., Zhuang, Y., Zhang, X., Li, M., Zhang, X., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282211 · Cited by 11
Effective Synthesis of High-Integrity mRNA Using In Vitro Transcription
He, W., Zhang, X., Zou, Y., Li, J., Wang, C., He, Y.-C., Jin, Q., & Ye, J. (2024) · Molecules · doi:10.3390/molecules29112461 · Cited by 13
Kiss, D. J., Oláh, J., Tóth, G., Varga, M., Stirling, A., Menyhárd, D. K., & Ferenczy, G. G. (2022) · ACS Catalysis · doi:10.1021/acscatal.1c04870 · Cited by 11
Testa, S., Haabeth, O. A. W., Blake, T. R., Castillo, T. J. D., Czerwinski, D. K., Rajapaksa, R., Wender, P. A., Waymouth, R. M., & Levy, R. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00469 · Cited by 11
Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases
Córdoba, K. M., Jericó, D., Sampedro, A., Jiang, L., Iraburu, M. J., Martini, P. G. V., Berraondo, P., Avila, M. A., & Fontanellas, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.03.005 · Cited by 11
Miliotou, Α. N., Georgiou‐Siafis, S. K., Ntenti, C., Pappas, I. S., & Papadopoulou, L. C. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110576 · Cited by 12
Qin, Q., Yan, H., Gao, W., Cao, R., Liu, G., Zhang, X., Wang, N., Zuo, W., Yuan, L., Gao, P., et al. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168822 · Cited by 11
Selective RNA pseudouridinylation in situ by circular gRNAs in designer organelles
Schartel, L., Jann, C., Wierczeiko, A., Butto, T., Mündnich, S., Marchand, V., Motorin, Y., Helm, M., Gerber, S., & Lemke, E. A. (2024) · Nature Communications · doi:10.1038/s41467-024-53403-1 · Cited by 10
The Bright Future of mRNA as a Therapeutic Molecule
Vélez, D. E., Torres, B. L., & Hernández, G. (2025) · Genes · doi:10.3390/genes16040376 · Cited by 11
Liu, Y., Krishnan, M. N., & Phua, K. K. L. (2017) · Biomolecules · doi:10.3390/biom7030056 · Cited by 10
New directions for Ψ and m1A decoding in mRNA: deciphering the stoichiometry and function
Zhang, M., Zhang, X., Ma, Y., & Yi, C. (2024) · RNA · doi:10.1261/rna.079950.124 · Cited by 10
Morphology evolution of lipid nanoparticle discovered by small angle neutron scattering
Li, Y., Ma, C., Han, Z., Weng, W., Yang, S., He, Z., Li, Z., Su, X., Zuo, T., & Cheng, H. (2024) · Giant · doi:10.1016/j.giant.2024.100329 · Cited by 10
Liu, Y., Chia, Z. H., Liew, J. N. M. H., Or, S. M., & Phua, K. K. L. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0712 · Cited by 11
3′-Modification stabilizes mRNA and increases translation in cells
Gampe, C. M., Seila, A. C., Siva, S., Zécri, F. J., & Diener, J. L. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.06.008 · Cited by 10
MicroRNA-dependent suppression of biological pacemaker activity induced by TBX18
Sanchez, L., Mesquita, T., Zhang, R., Liao, K., Rogers, R. G., Lin, Y., Miguel‐dos‐Santos, R., Akhmerov, A., Li, L., Nawaz, A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100871 · Cited by 10
Noble Nanomedicine: Celebrating Groundbreaking mRNA Vaccine Innovations
Chan, W. C. W., Artzi, N., Chen, C., Chen, X., Ho, D., Hu, Y., Kataoka, K., Liz‐Marzán, L. M., Öklü, R., & Parak, W. J. (2023) · ACS Nano · doi:10.1021/acsnano.3c09781 · Cited by 10
Regulatory perspective for quality evaluation of lipid nanoparticle-based mRNA vaccines in China
Lu, J., Wei, W., & He, W. (2023) · Biologicals · doi:10.1016/j.biologicals.2023.101700 · Cited by 9
Adachi, T., Tahara, Y., Yamamoto, K., Yamamoto, T., Kanamura, N., Akiyoshi, K., & Mazda, O. (2024) · Gels · doi:10.3390/gels10030206 · Cited by 9
McMinn, S. E., Miller, D. V., Yur, D., Stone, K., Xu, Y., Vikram, A., Murali, S., Raffaele, J., Holland, D., Wang, S.-C., et al. (2024) · Biochemistry · doi:10.1021/acs.biochem.4c00188 · Cited by 9
From Sequence to System: Enhancing IVT mRNA Vaccine Effectiveness through Cutting-Edge Technologies
Xu, L., Li, C., Liao, R., Xiao, Q., Wang, X., Zhao, Z., Zhang, W., Ding, X., Cao, Y., Cai, L., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00863 · Cited by 9
Campos, C. M., Lanz‐Mendoza, H., Cime‐Castillo, J., Peralta-Zaragoza, Ó., & Madrid‐Marina, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26114964 · Cited by 10
Therapeutic Application of mRNA for Genetic Diseases
Schürmann, P. J. L., Vriesman, S. V. B., Castro-Alpízar, J., Kooijmans, S. A. A., Nieuwenhuis, E. E. S., Schiffelers, R. M., & Fuchs, S. A. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70019 · Cited by 9
RNA modifications in health and disease: from mechanistic insights to therapeutic applications
Chen, Y., Ding, D., Tang, X., Ma, R., & Zhou, J. (2025) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaf035 · Cited by 11
Eladl, O., Abdelhady, A., & TagElDein, M. A. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153673 · Cited by 9
Nagaraj, S., Stankiewicz-Drogoń, A., Darżynkiewicz, E., & Grzela, R. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1017934 · Cited by 9
Kondhare, D., Zhang, A., Leonard, P., & Seela, F. (2022) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c00812 · Cited by 9
mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19
Kackos, C. M., Surman, S. L., Jones, B. G., Sealy, R. E., Jeevan, T., Davitt, C. J. H., Pustylnikov, S., Darling, T. L., Boon, A. C. M., Hurwitz, J. L., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04240-22 · Cited by 9
RNA recognition by PKR during DNA virus infection
Zhang, R., & Karijolich, J. J. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29424 · Cited by 9
LinearDesign: Efficient Algorithms for Optimized mRNA Sequence DesignPreprint
Zhang, H., Zhang, L., Li, Z., Liu, K., Liu, B., Mathews, D. H., & Huang, L. (2020) · arXiv (Cornell University) · Cited by 8
The Nobel Prize in Physiology or Medicine 2023
Jónsdóttir, I. (2023) · Læknablaðið · doi:10.17992/lbl.2023.12.769 · Cited by 9
Metadata
- Authors
- Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H., Weissman, D., & Karikó, K.
- Affiliations
- Pennsylvania State University (US)
- Corresponding author
- Karikó, Katalin
- ORCID
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-05-10
- Volume
- 38
- Issue
- 17
- Pages
- 5884-5892
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC2943593
- OpenAlex
- W2156788486
- Cited by
- 682
- References
- 60
- Citations by year
- 2026: 67 · 2025: 99 · 2024: 143 · 2023: 90 · 2022: 77 · 2021: 52 · 2020: 22 · 2019: 22 · 2018: 26 · 2017: 17 · 2016: 21 · 2015: 13 · 2014: 6 · 2013: 12 · 2012: 8
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Cleveland Clinic
- Cleveland Clinic Foundation
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R42HL087688)
- National Institute of General Medical Sciences (T32GM007229, R01GM058709)
- National Institute of Allergy and Infectious Diseases (R01AI050484)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007748)
- National Institute of Dental and Craniofacial Research (R21DE019059)
- National Center for Research Resources (T32RR007063)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- pseudouridine, mRNA translation, PKR, RNA-dependent protein kinase, eIF2α phosphorylation, translation initiation, uridine, in vitro transcribed mRNA, RNA-protein interactions
- MeSH terms
- Animals, Cell Line, Cells, Cultured, Humans, Pseudouridine, RNA, Messenger, Protein Biosynthesis, eIF-2 Kinase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
